Equillium Inc
NASDAQ:EQ

Watchlist Manager
Equillium Inc Logo
Equillium Inc
NASDAQ:EQ
Watchlist
Price: 1.07 USD 18.89%
Market Cap: 65.2m USD

Operating Margin
Equillium Inc

-554.9%
Current
-111%
Average
-3.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-554.9%
=
Operating Profit
-24.4m
/
Revenue
4.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Equillium Inc
NASDAQ:EQ
64.9m USD
-555%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
398B USD
33%
US
Amgen Inc
NASDAQ:AMGN
169.7B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.5B USD
28%
AU
CSL Ltd
ASX:CSL
86.6B AUD
26%
NL
argenx SE
XBRU:ARGX
46.4B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.3B USD
8%
No Stocks Found

Equillium Inc
Glance View

Market Cap
64.9m USD
Industry
Biotechnology

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.

EQ Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-554.9%
=
Operating Profit
-24.4m
/
Revenue
4.4m
What is the Operating Margin of Equillium Inc?

Based on Equillium Inc's most recent financial statements, the company has Operating Margin of -554.9%.

Back to Top